tiprankstipranks
Gilead price target raised to $80 from $69 at Baird
The Fly

Gilead price target raised to $80 from $69 at Baird

Baird analyst Brian Skorney raised the firm’s price target on Gilead to $80 from $69 and keeps a Neutral rating on the shares. The analyst said Gilead put up a strong finish to the year as HIV continues to grow, while retaining its dominance and despite concerns on the cost of getting there, Gilead’s oncology sales provide a material source of revenue.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on GILD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles